SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Berg Christine D)) pers:(Stevens Victoria L)
 

Search: (WFRF:(Berg Christine D)) pers:(Stevens Victoria L) > (2020-2023) > Design and methodol...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00011938naa a2201045 4500
001oai:DiVA.org:umu-201376
003SwePub
008221130s2023 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-2013762 URI
0247 a https://doi.org/10.1016/j.annepidem.2022.10.0142 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Robbins, Hilary A.u Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
2451 0a Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program
264 1b Elsevier,c 2023
338 a electronic2 rdacarrier
520 a The Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program is an NCI-funded initiative with an objective to develop tools to optimize low-dose CT (LDCT) lung cancer screening. Here, we describe the rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL. The overarching goal of these projects is to systematically investigate circulating protein markers to include on a panel for use (i) pre-LDCT, to identify people likely to benefit from screening, and (ii) post-LDCT, to differentiate benign versus malignant nodules. To identify informative proteins, the Risk Biomarker project measured 1161 proteins in a nested-case control study within 2 prospective cohorts (n = 252 lung cancer cases and 252 controls) and replicated associations for a subset of proteins in 4 cohorts (n = 479 cases and 479 controls). Eligible participants had a current or former history of smoking and cases were diagnosed up to 3 years following blood draw. The Nodule Malignancy project measured 1078 proteins among participants with a heavy smoking history within four LDCT screening studies (n = 425 cases diagnosed up to 5 years following blood draw, 430 benign-nodule controls, and 398 nodule-free controls). The INTEGRAL panel will enable absolute quantification of 21 proteins. We will evaluate its performance in the Risk Biomarker project using a case-cohort study including 14 cohorts (n = 1696 cases and 2926 subcohort representatives), and in the Nodule Malignancy project within five LDCT screening studies (n = 675 cases, 680 benign-nodule controls, and 648 nodule-free controls). Future progress to advance lung cancer early detection biomarkers will require carefully designed validation, translational, and comparative studies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a biomarker discovery and validation
653 a biomarkers
653 a early detection
653 a Lung cancer screening
653 a nodule malignancy
653 a risk prediction
653 a study design
7001 a Alcala, Karineu Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Moez, Elham Khodayariu Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada4 aut
7001 a Guida, Florenceu Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Thomas, Serau Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada4 aut
7001 a Zahed, Hanau Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Warkentin, Matthew T.u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada4 aut
7001 a Smith-Byrne, Karlu Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom4 aut
7001 a Brhane, Yonathanu Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada4 aut
7001 a Muller, Davidu Division of Genetic Medicine, Imperial College London School of Public Health, London, United Kingdom4 aut
7001 a Feng, Xiaoshuangu Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Albanes, Demetriusu Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Aldrich, Melinda C.u Department of Medicine, Vanderbilt University Medical Center, TN, Nashville, United States4 aut
7001 a Arslan, Alan A.u Departments of Obstetrics and Gynecology and Population Health, New York University Grossman School of Medicine, NY, New York, United States4 aut
7001 a Bassett, Julieu Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia4 aut
7001 a Berg, Christine D.u Retired, MD, Bethesda4 aut
7001 a Cai, Qiuyinu Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, TN, Nashville, United States4 aut
7001 a Chen, Chuu Program in Epidemiology and the Women's Health Initiative Clinical Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, WA, Seattle, United States4 aut
7001 a Davies, Michael P.A.u Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom4 aut
7001 a Diergaarde, Brendau Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, PA, Pittsburgh, United States; UPMC Hillman Cancer Centre, PA, Pittsburgh, United States4 aut
7001 a Field, John K.u Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom4 aut
7001 a Freedman, Neal D.u Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Huang, Wen-Yiu Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Johansson, Mikaelu Umeå universitet,Onkologi4 aut0 (Swepub:umu)mijo0025
7001 a Jones, Michaelu Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom4 aut
7001 a Koh, Woon-Puayu Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore, Singapore4 aut
7001 a Lam, Stephenu Integrative Oncology, British Columbia Cancer Agency, Vancouver, Canada4 aut
7001 a Lan, Qingu Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Langhammer, Arnulfu HUNT Research Center, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway4 aut
7001 a Liao, Linda M.u Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Liu, Geoffreyu Computational Biology and Medicine Program, Princess Margaret Cancer Center, Toronto, Canada4 aut
7001 a Malekzadeh, Rezau Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran4 aut
7001 a Milne, Roger L.u Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia; School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia4 aut
7001 a Montuenga, Luis M.u Center of Applied Medical Research (CIMA) and Schools of Sciences and Medicine, University of Navarra, Pamplona, Spain; IDISNA, Pamplona, Spain; CIBERONC, Madrid, Spain4 aut
7001 a Rohan, Thomasu Department of Epidemiology & Population Health, Albert Einstein College of Medicine, NY, Bronx, United States4 aut
7001 a Sesso, Howard D.u Brigham and Women's Hospital, Harvard Medical School, MA, Boston4 aut
7001 a Severi, Gianlucau Inserm, Université Paris-Saclay, Villejuif, France4 aut
7001 a Sheikh, Mahdiu Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Sinha, Rashmiu Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a Shu, Xiao-Ouu Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, TN, Nashville, United States4 aut
7001 a Stevens, Victoria L.u Rollins School of Public Health, Emory University, GA, Atlanta4 aut
7001 a Tammemägi, Martin C.u Department of Health Sciences, Brock University, ON, St. Cathaarines, Canada; Prevention and Cancer Control, Ontario Health, ON, Toronto, Canada4 aut
7001 a Tinker, Lesley F.u Women's Health Initiative Clinical Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, WA, Seattle, United States4 aut
7001 a Visvanathan, Kalau Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, MD, Baltimore4 aut
7001 a Wang, Yingu American Cancer Society, GA, Atlanta4 aut
7001 a Wang, Renweiu UPMC Hillman Cancer Center, University of Pittsburgh, PA, Pittsburgh, United States4 aut
7001 a Weinstein, Stephanie J.u Division of Cancer Epidemiology and Genetics, National Cancer Institute, MD, Rockville4 aut
7001 a White, Emilyu Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, WA, Seattle, United States4 aut
7001 a Wilson, Davidu Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, PA, Pittsburgh, United States4 aut
7001 a Yuan, Jian-Minu UPMC Hillman Cancer Centre, PA, Pittsburgh, United States; Department of Epidemiology, Graduate Schoolf of Public Health, University of Pittsburgh, PA, Pittsburgh, United States4 aut
7001 a Zhang, Xuehongu Brigham and Women's Hospital, Harvard Medical School, MA, Boston4 aut
7001 a Zheng, Weiu Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, TN, Nashville, United States4 aut
7001 a Amos, Christopher I.u Institute for Clinical and Translational Research, Baylor College of Medicine, TX, Houston, United States4 aut
7001 a Brennan, Paulu Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Johansson, Mattiasu Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France4 aut
7001 a Hung, Rayjean J.u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada4 aut
7102 a Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, Franceb Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada4 org
7730 t Annals of Epidemiologyd : Elsevierg 77, s. 1-12q 77<1-12x 1047-2797x 1873-2585
8564 u https://doi.org/10.1016/j.annepidem.2022.10.014y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1714686/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-201376
8564 8u https://doi.org/10.1016/j.annepidem.2022.10.014

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view